Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

This Phase II study assessed feasibility and efficacy of a biweekly R-COMP-14 regimen (rituximab, cyclophosphamide, non-pegylated liposome-encapsulated doxorubicin, vincristine and prednisone) in untreated elderly patients with poor-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high ‘li...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Corazzelli, Gaetano, Frigeri, Ferdinando, Arcamone, Manuela, Lucania, Anna, RosariaVilla, Maria, Morelli, Emanuela, Amore, Alfonso, Capobianco, Gaetana, Caronna, Antonietta, Becchimanzi, Cristina, Volzone, Francesco, Marcacci, Gianpaolo, Russo, Filippo, De Filippi, Rosaria, Mastrullo, Lucia, Pinto, Antonio
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Blackwell Publishing Ltd 2011
विषय:
Haematological Malignancy
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3258483/
https://ncbi.nlm.nih.gov/pubmed/21707585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08786.x
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन